Affimed NV
NASDAQ:AFMD
Affimed NV
NASDAQ:AFMD
Price:
5.16 USD
-1.71%
Market Closed
Updated:
May 21, 2024
Section:
Relative Value
The Relative Value of one
AFMD
stock under the Base Case scenario is
8.09
USD.
Compared to the current market price of 5.16 USD,
Affimed NV
is
Undervalued by 36%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AFMD
Relative Value
Base Case
8.09
USD
Undervaluation 36%
Valuation Multiples
Multiples Across Competitors
AFMD Competitors Multiples
Affimed NV Competitors
Affimed NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Affimed NV
NASDAQ:AFMD
|
77.1m USD | 8.6 | -0.7 | -0.1 | -0.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.6B USD | 5.3 | 48.8 | 13.7 | 21.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.7B USD | 5.7 | 44.8 | 18.8 | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 11.3 | 28.7 | 24 | 25.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.8B USD | 8.3 | 28.2 | 22.8 | 25.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 3.1 | 174.8 | 8.8 | 11.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54B USD | 10.5 | -9 | -10.1 | -9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.7B USD | 3.5 | 28.9 | 14.7 | 18.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.7T KRW | 17.8 | 72.3 | 44.3 | 61 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
